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a b s t r a c t
The pneumococcus remains a common cause of otitis media (OM) despite the widespread introduction of
pneumococcal conjugate vaccines. In mice, a pneumococcal whole cell vaccine (WCV) induces serotype-
independent protection against pneumococcal colonisation and invasive disease via TH17- and antibody-
mediated immunity, respectively. We investigated the effect of WCV on influenza A-induced pneumococ-
cal OM in an infant mouse model.
C57BL/6 mice were immunised subcutaneously with a single dose of WCV or adjuvant at 6 days of age,
infected with pneumococci (EF3030 [serotype 19F] or PMP1106 [16F]) at 12 days of age, and given influ-
enza A virus (A/Udorn/72/307 [H3N2], IAV) at 18 days of age to induce pneumococcal OM. Pneumococcal
density in middle ear and nasopharyngeal tissues was determined 6 and 12 days post-virus. Experiments
were repeated in antibody (B6.lMT/)- and CD4+ T-cell-deficient mice to investigate the immune
responses involved.
A single dose of WCV did not prevent the development of pneumococcal OM, nor accelerate pneumo-
coccal clearance compared with mice receiving adjuvant alone. However, WCV reduced the density of
EF3030 in the middle ear at 6 days post-viral infection (p = 0.022), and the density of both isolates in
the nasopharynx at 12 days post-viral infection (EF3030, p = 0.035; PMP1106, p = 0.011), compared with
adjuvant alone. The reduction in density in the middle ear required antibodies and CD4+ T cells: WCV did
not reduce EF3030 middle ear density in B6.lMT/mice (p = 0.35) nor in wild-type mice given anti-CD4
monoclonal antibody before and after IAV inoculation (p = 0.91); and WCV-immunised CD4+ T cell-
deficient GK1.5 mice had higher levels of EF3030 in the middle ear than their adjuvant-immunised coun-
terparts (p = 0.044).
A single subcutaneous dose of WCV reduced pneumococcal density in the middle ears of co-infected
mice in one of two strains tested, but did not prevent OM from occurring in this animal model.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Otitis media (infection of the middle ear; OM) is a common pae-
diatric condition, and Streptococcus pneumoniae (pneumococcus) is
a leading cause [1,2]. OM typically ariseswhen bacteria disseminate
from the nasopharynx, where the pneumococcus resides in up to
90% of healthy children under the age of five [3], to the middle ear
cavity via the Eustachian tube. Young children suffer the highest
rates ofOM. Pneumococcal conjugate vaccines (PCVs) induce immu-
nity against the pneumococcal polysaccharide capsule and are
highly effective against invasive pneumococcal disease [4]. How-
ever, their impact onOMhas beenmore variable. Clinical trials eval-
uating the effect of the 7- and 13-valent PCVs demonstrated a 25–
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56% reduction in acute otitis media (AOM) caused by any pneumo-
coccus, and a60% reduction in AOM caused by PCV-type pneumo-
cocci [5–7]. Importantly, PCVs only protect against a small subset of
pneumococcal serotypes and their use has led to increases in disease
caused by non-vaccine serotypes [8]. Alternative vaccines which
induce protection against non-capsular pneumococcal antigens
may provide enhanced protection against OM compared to PCVs.
The pneumococcal whole cell vaccine (WCV) consists of a killed,
unencapsulated pneumococcal strain delivered with adjuvant [9].
WCVwas developed to induce broad protection against all pneumo-
cocci at low cost. Preclinical studies have demonstrated WCV to be
protective against both invasive pneumococcal disease and coloni-
sation in mice [9,10] and have provided sufficient evidence to allow
the progression of WCV into clinical trials [11]. Only one preclinical
study has examined the ability of WCV to prevent pneumococcal
OM.Malley et al. tested the effect of two or three doses ofWCV, con-
sisting of ethanol-killed whole cell antigen (WCA) combined with
various adjuvants, given intranasally (i.n.) to adult mice before i.n.
challenge with pneumococci [12]. Pneumococcal density was enu-
merated in nasopharyngeal and middle ear washes one week after
challenge and compared to that in mice which received adjuvant
alone. Each schedule of WCV (with cholera toxin adjuvant) signifi-
cantly reduced the number ofmice colonisedwith a serotype 6B iso-
late, and also reduced the density of nasopharyngeal colonisation
[12]. Further, WCV significantly protected mice from middle ear
infection with a serotype 23F isolate [12]. Despite these promising
results, it is unclearwhetherWCV prevented themigration of pneu-
mococci into themiddle ear, or ifWCV-mediated responses acceler-
ated the clearance of pneumococci following the development of
infection, as was observed for WCV-mediated protection against
colonisation [13]. Moreover, the immune mechanisms involved in
protection of WCV against OM have not been investigated.
Co-infection with a respiratory virus is associated with OM in
young children [14,15]. We have developed an infant mouse model
of pneumococcal OM [16] in which pneumococcal colonisation is
induced experimentally by delivering a small dose of the bac-
terium to the nares of an unanaesthetised animal. Pneumococci
remain localised in the upper respiratory tract for approximately
five weeks [17], mimicking a carriage episode similar to that
observed in young children [18,19]. Subsequent i.n. co-infection
of colonised mice with influenza A virus (IAV) causes pneumococci
to multiply in the nasopharynx and disseminate to the middle ear
cavity, resulting in OM and hearing loss [16]. In this study, we
adapted this model to investigate the effect of WCV on IAV-
induced pneumococcal OM in infant mice.
2. Materials and methods
2.1. Animals
All animal experiments were approved by the Animal Ethics
Committee of the University of Melbourne (1413144) and were
conducted in accordance with the Prevention of Cruelty to Animals
Act (1986) and the Australian National Health and Medical
Research Council Code of Practice for the Care and Use of Animals
for Scientific Purposes (2013). C57BL/6 (WT), B6.lMT/ and GK1.5
mice were bred and housed at the Biological Resources Facility
(BRF), Department of Microbiology and Immunology at The Peter
Doherty Institute for Infection and Immunity, The University of
Melbourne, Australia. Litters of mice were housed in ventilated
cages with unlimited access to sterile food and water.
2.2. Bacterial and viral strains
Pneumococcal isolates EF3030 (serotype 19F) and PMP1106
(serotype 16F) were passaged in mice and recovered from the
nasopharynx before experimental use. IAV strain A/Udorn/72/307
(H3N2, A/Ud/72) was used in all experiments. Bacterial and viral
infectious stocks were prepared as described previously [20].
2.3. Vaccine
WCV was prepared as described previously [21]. Whole cell
antigen (WCA) consisted of pneumococcal strain RM200 (a deriva-
tive of the unencapsulated pneumococcal strain RX1E containing a
non-toxic pneumolysoid and deletion of the autolysin gene [22])
killed by treatment with beta-propiolactone. Each 100 ll WCV
dose contained 100 lg of WCA and 2.5 lg/ll aluminium phos-
phate (Alhydrogel [Brenntag]) in sterile saline. In all vaccination
experiments the effects of WCV were compared to a group of mice
receiving the same dose of Alhydrogel in 100 ll of saline
(adjuvant).
2.4. Otitis media model
Litters of 12-day-old mice were infected i.n. with 2  103 CFU
of pneumococci in 3 ll of PBS followed by i.n. infection with 102.5
PFU of IAV in 3 ll of PBS 6 days later. In vaccination experiments,
mice were first immunised with WCV or adjuvant via subcuta-
neous injection to the back of the neck at 6 days of age, followed
by co-infection as described above. Mice were euthanised by CO2
inhalation at predetermined time points post-infection. Nasopha-
ryngeal and middle ear tissue were collected for enumeration of
pneumococci by culture on gentamicin horse blood agar as
described previously [20]. IAV was quantified by reverse transcrip-
tase qPCR (RTqPCR, see below). Blood samples and spleens were
harvested and analysed for immune responses as described below.
To obtain plasma, whole blood was collected in heparinised tubes
and samples were incubated overnight at 4 C. Red blood cells
were removed by centrifugation (2400 x g for 5 min followed by
a further 11,300 x g at 4 C for 5 min). Samples were stored at
80 C until tested. To obtain single cell suspensions of spleno-
cytes, spleens were mechanically disassociated by passing the tis-
sue through a 70 lm cell strainer (Falcon). Splenocytes were
collected by centrifugation (350 x g at 4 C for 5 min) and resus-
pended in 2 ml of TAC buffer (containing a final concentration of
17 mM Tris and 140 mM ammonium chloride) at room tempera-
ture for 10 min with infrequent inversion to lyse red blood cells.
RPMI 1640 medium (Sigma-Aldrich) was added to each sample
to stop the reaction and splenocytes were washed and collected
by centrifugation as above and resuspended in 1 ml Dulbecco’s
Modified Essential Medium with Ham’s F12 medium (DMEM/F12
[Gibco]).
To investigate the immune mechanisms involved in mediating
WCV effects on pneumococcal OM, mice deficient in antibodies
(B6.lMT/ mice [23]), CD4+ T cells (GK1.5 mice [24]), or CD4+ T
cells at the time of OM (WT mice treated with GK1.5 monoclonal
antibody [mAb]) were co-infected as described above with addi-
tional modifications. As previous studies have determined that
antibodies are required for the development of OM in co-infected
B6.lMT/ mice [25], such mice were administered serum
obtained from naive WT adult mice via intraperitoneal (i.p.) injec-
tion one day before, and each day following, IAV infection (aged 17,
19–23 days-old respectively). To deplete CD4+ T cells at the time of
OM induction, GK1.5 mAb (Walter and Eliza Hall Institute [WEHI])
was administered via i.p. injection one day before, and two days
after, IAV infection (aged 17 and 20 days-old respectively). Each
dose consisted of 125 lg of antibody per 10 g of body weight in a
total volume of 50 ll. The mAb rat isotype IgG2b antibody (WEHI)
was administered to a control group at the same concentration to
control for non-specific effects of antibody injection.
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2.5. IAV RTqPCR
To quantify viral loads in mouse samples, tissues were pro-
cessed as described previously [20] and viral RNA was extracted
using the QIAamp viral RNA Mini Kit (Qiagen) according to the
manufacturer’s instructions. RNA was used as a template for one-
step cDNA synthesis and RTqPCR using previously published pri-
mer and probe sequences amplifying the matrix gene of IAV [26].
RTqPCR reactions were performed in duplicate using the Strata-
gene MxPro 3005. Each 20 ll reaction contained 4 ll of extracted
RNA, 10 ll of SensiFAST probe No-ROX one-step master mix,
0.2 ll of reverse transcriptase, 0.2 U/ll RiboSafe RNase inhibitor
(all Bioline), 400 nM of each primer (Sigma-Aldrich) and 100 nM
probe (Sigma-Aldrich). RTqPCR conditions were as follows: 1 cycle
of 10 min at 45 C and 1 cycle of 2 min at 95 C followed by 40
cycles of 5 s at 95 C and 20 s at 60 C. To quantify the number of
matrix gene copies in each sample, plasmid DNA extracted from
an E. coli strain transformed with the 4007 bp pHW plasmid con-
taining the matrix protein from Ud/A/72 (XLI-B pHWUd/A/72ma-
trix) was used to generate a standard curve. IAV loads are
expressed as genome copies/ml based on 1 mg of plasmid DNA
being equivalent to 227.7 IAV virions (assuming one copy of the
matrix gene was present in each E. coli plasmid).
2.6. Histology
To analyse inflammation in the middle ear cavity, haematoxylin
and eosin-staining was performed [58]. Mice were euthanised and
were perfused intracardially with 0.4 g/L paraformaldehyde. The
middle ears were dissected and fixed for at least 1 h in 0.4 g/L
paraformaldehyde (Sigma-Aldrich). Tissues were washed three
times in Tris Buffered Saline (TBS), containing a final concentration
of 0.05 M Tris-HCl [Sigma-Aldrich] and 9 g/L sodium chloride
[Sigma-Aldrich], pH 7.6. Tissues were then incubated for seven
days in decalcification buffer (100 g/L EDTA [Sigma-Aldrich] in
PBS, pH 7.2–7.4) before infiltration with TBS containing 3 g/L
sucrose. Decalcified tissues were embedded in a 1:1 ratio of TBS
+ 3 g/L sucrose and Tissue-Tek Optimal Cutting Temperature
compound (OCT [Sakura Finetek Inc]) overnight at 4 C before
being transferred to pure OCT and further incubated overnight at
4 C. OCT was solidified using isopentane in a container with liquid
nitrogen. Sections of 2 lm tissue were cut using the HM525 NX
Cryostat (ThermoFisher Scientific), fixed onto glass slides and
stained with hae matoxylin (Sigma-Aldrich) for 2 min to identify
cell nuclei, washed in distilled water, and then Scott’s tap water
(Sigma-Aldrich) was applied for 1 min. Sections were washed in
distilled water and then counterstained with 10 g/L eosin (Sigma-
Aldrich) and washed again with distilled water. Slides were dehy-
drated with absolute ethanol (3  1 min), cleared with xylene
(3  1 min [Sigma-Aldrich]) and mounted with a coverslip. Slides
were visualised using the Leica DM 1000 light microscope (Leica
Microsystems) and scored blindly for inflammatory infiltrate in
the middle ear cavity by an independent pathologist as described
previously [16].
2.7. ELISA and ex vivo stimulation of whole blood
WCA-specific IgG was detected in plasma or in whole blood fol-
lowing ex vivo stimulation with vaccine antigen (WCA), or PBS as a
control, using the method described by Lu et al. [9] with some
modifications. 96-well ELISA plates (Maxisorp immuno plate
[Nunc]) were coated overnight with 100 lg of WCA and blocked
with 10 g/L BSA in PBST (PBS + 0.5 ml/L Tween20 [Sigma-
Aldrich]). Samples were diluted in PBST and added to duplicate
wells for 2 h at 37 C. Anti-mouse IgG biotin-conjugated antibody
(Sigma-Aldrich) was added to each well at a dilution of 1 in
5000, and plates were incubated for 1 h at 37 C. To detect
antigen-IgG complexes, wells were washed and horseradish perox-
idase (HRP)-labelled Streptavidin (Streptavidin-HRP [KPL]) was
added to each well at a dilution of 1 in 5000 and incubated for
1 h at room temperature. Bound streptavidin-HRP was visualised
using TMB substrate (KPL) and the optical density at 450 nm was
read using a CLARIOstar plate reader (BMG Labtech) or an
ELx808 Absorbance reader (BioTek). A standard curve was run on
each plate using a 1 in 2 dilution series of positive control sera col-
lected from adult mice which had received two subcutaneous
doses of WCV at two-week intervals, two weeks after the second
dose. A 1 in 1000 dilution of the control sera was assigned a value
of 1000 arbitrary units (AU), and anti-WCA IgG responses in sam-
ples were interpolated from the standard curve.
IL-17A was measured in supernatants from splenocytes stimu-
lated as described previously [13] using the Quantikine Mouse
IL-17 ELISA kit (R&D Systems Inc.) according to the manufacturer’s
instructions.
2.8. Flow cytometry
The depletion of CD4+ T cells in mice treated with GK1.5 or rat
IgG2b mAb antibody was confirmed by flow cytometry. Spleno-
cytes were prepared as described above and labelled with fluo-
rochrome conjugated antibodies specific for cell surface markers
CD4 (clone RM4.4 [BD Horizon]), CD3 (clone 17A2 [BD Horizon])
and Thy1.2 (clone 53-2.1 [eBioscience]). The splenocyte samples
were analysed using an LSRII flow cytometer (BD Bioscience)
according to the manufacturer’s instructions. Dead cells were
identified and excluded in each sample by the addition of
1 lg/106 cells of propidium iodide (PI [Sigma-Aldrich]) immedi-
ately before analysis. For all samples, 1  105 events were collected
and recorded.
2.9. Statistics
Data were analysed using GraphPad Prism version 6.0 h for
MacIntosh and Stata version 15.1. Experimental groups were com-
pared using the MannWhitney U Test (Prism). A two-tailed Fisher’s
exact test was used to compare differences in the number of mice
which developed unilateral OM, bilateral OM or no OM (Stata). The
statistical test used for each analysis is indicated in the accompa-
nying text and figure legends. P values less than 0.05 were consid-
ered statistically significant.
3. Results
To investigate the effect of WCV immunisation on OM, we first
adapted our published model [16]. Mice were colonised with pneu-
mococci at 12 days of age and then infected with IAV at 18 days of
age (Fig. 1A). Pneumococcal isolates were chosen to represent ser-
otypes that are commonly carried (19F) or that have been increas-
ingly detected (16F) in carriage and OM in high-risk populations
following PCV introduction [27,28]. Both pneumococcal isolates
tested (EF3030 and PMP1106) were able to disseminate to the mid-
dle ears post-IAV administration (Fig. 1B and C). Co-infection
induced pneumococcal OM in 16 of 17 mice colonised with
EF3030 (94.1%) and 17 of 18 mice colonised with PMP1106
(94.4%) at six days post-IAV. The majority of mice had cleared
the bacteria from the middle ears by 14 days post-IAV infection
(Fig. 1B and C). Six days after IAV-infection, most co-infected mice
had bilateral pneumococcal OM, regardless of the pneumococcal
isolate used (Fig. 1D and E). During clearance, the proportion of
mice with bilateral OM decreased, with a resultant increase in mice
with unilateral and then no OM (Fig. 1D and E), indicating that
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co-infected mice clear pneumococci from each ear independently.
IAV was only detected in the middle ears of 2 of 32 (EF3030) and 2
of 26 (PMP1106) co-infected mice at 6 days post-IAV and was not
detected in the middle ears after this time point.
To evaluate the effect of WCV on IAV-induced pneumococcal
OM at the peak of disease, infant mice were vaccinated with a sin-
gle subcutaneous dose of WCV (or adjuvant) to the back of the neck
at 6 days of age, and then co-infected as shown in Fig. 1A. Pneumo-
coccal and IAV density was measured in nasopharyngeal and mid-
dle ear tissue 6 days after infection with IAV. WCV significantly
reduced the density of EF3030 in the middle ears of co-infected
mice (Fig. 2A, p = 0.022), despite the mice having comparable
levels of IAV at this site (Fig. 2C, p = 0.93). In 4 of 21 (19%) of
WCV-immunised mice, EF3030 was not detected in either ear,
whereas all 18 mice treated with adjuvant had detectable EF3030
in at least one ear (Table 1). Of mice with detectable EF3030 in
any ear, bilateral OM was observed in 11 of 21 (52%) of mice
administered WCV compared to 13 of 18 (72%) of the adjuvant
control group (Table 1). No significant differences were observed
in the median density of EF3030 in the nasopharynx (Fig. 2A,
p = 0.093), or in IAV levels in the nasopharynx or middle ears of
adjuvant- and WCV-treated mice.
In contrast to results observed with EF3030, WCV did not
reduce PMP1106 density in the middle ears of co-infected mice
(Fig. 2B, p = 0.47). In 2 of 21 WCV-immunised mice PMP1106
was not detected in either ear, whereas all 18 mice immunised
with adjuvant had detectable PMP1106 in at least one ear (Table 1).
There were no differences in the proportion of mice displaying
bilateral OM (Table 1: 11 of 18 (61%) vs 13 of 21 (62%)), in the med-
ian density of PMP1106 in the nasopharynx (Fig. 2B, p = 0.34), or in
the proportion of mice exhibiting nasopharyngeal loads of less
than 105 CFU between vaccine groups (4 of 21 (19%) vs 4 of 18
(22%)). Nasopharyngeal IAV loads were comparable between mice
administered WCV or adjuvant and co-infected with PMP1106
(Fig. 2D, p = 0.63).
Interestingly (Fig. 2), mice had differing IAV loads in the
nasopharynx depending on whether they were co-infected with
EF3030 or PMP1106. This was the case for both adjuvant-treated
mice (EF3030 median 1.88 x 107 IAV genome copies vs PMP1106
median 3.00 x 106 IAV genome copies, p = 0.0008, Mann Whitney
U test) and WCV-treated mice (EF3030 median 7.76 x 106 IAV gen-
ome copies vs PMP1106 median 3.35 x 106 IAV genome copies,
p = 0.0169, Mann U Whitney test).
Preliminary histological analysis revealed no significant differ-
ences in inflammation of the middle ear between WCV-
immunised and adjuvant control groups for mice co-infected with
EF3030 (20% vs 50%, p = 0.69) or PMP1106 (0% vs 10%, p = 0.67).
To investigate whether WCV accelerated the clearance of pneu-
mococci from the middle ears, we compared mice given adjuvant
alone with those immunised with WCV 12 days after infection
Fig. 1. Development and clearance of OM in mice co-infected with pneumococci and IAV. Mice were co-infected with pneumococci and IAV (A). At various time points post-
IAV infection, pneumococcal density in the middle ear tissues was determined in mice colonised with EF3030 (B) or PMP1106 (C). Counts from each middle ear are
represented as individual data points with red lines depicting the median. The dotted line represents the limit of detection (100 CFU). The proportion of co-infected mice with
EF3030 (D) or PMP1106 (E) detected in neither (no OM, white bars), one (unilateral OM, grey bars) or both (bilateral OM, black bars) middle ears over time was determined.
The error bars show the 95% confidence interval of the median. All graphs show data pooled from at least two independent experiments per time point. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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with IAV, and found no difference in the number of mice that
developed OM (Table 1, EF3030: 14 of 25 (56%) vs 12 of 20
(60%); PMP1106: 13 of 21 (62%) vs 10 of 18 (56%)), nor the levels
of pneumococci in their middle ears (Fig. 3A, p = 0.61; Fig. 3B,
p = 0.22). No significant differences were observed between IAV
loads in the middle ears of mice administered WCV or adjuvant
(Fig. 3C, p = 1; Fig. 3D, p = 0.88) 12 days post-IAV infection. How-
ever, a significant reduction in pneumococcal density was
observed in the nasopharynx of mice administered WCV, com-
pared to mice administered adjuvant, for both pneumococcal iso-
lates tested (Fig. 3A, p = 0.035; Fig. 3B, p = 0.011). This reduction
was observed despite comparable levels of IAV in the nasopharynx
among vaccine groups (Fig. 3C, p = 0.34; Fig. 3D, p = 0.63).
We next investigated the immune responses associated with
the observed reduction of EF3030 density in the middle ears. Pre-
vious studies in adult mice have demonstrated roles for CD4+ T
cells, and the cytokine IL-17A, in WCV-mediated protection against
pneumococcal colonisation [13,27]. We hypothesised that, since
the nasopharynx and the middle ear are both mucosal sites, CD4+
T cells and IL-17A would be involved in the observed WCV-
mediated reduction of EF3030 density in the middle ear. We there-
fore measured splenic IL-17A responses in vaccinated and co-
infected mice (EF3030) 6 days post-IAV infection. In vitro stimula-
tion of splenocytes with WCA induced significant production of IL-
17A compared to stimulation with PBS (Fig. 4A, p < 0.001 for both
adjuvant and WCV). In WCA-stimulated samples, we observed a
Fig. 2. Effect of WCV on pneumococcal OM six days post-IAV. Mice were administered one dose of either adjuvant (open squares) or WCV (closed squares) subcutaneously
and then co-infected with pneumococci (EF3030, left panel or PMP1106, right panel) and IAV as depicted in Fig. 1A. Pneumococcal (A, B) and IAV (C, D) levels in the
nasopharynx and middle ears were determined 6 days post-IAV infection. For the nasopharynx, each data point represents an individual mouse. Counts from each middle ear
are represented as individual data points. Figures show data pooled from three independent experiments. Red lines show the median; the dotted line represents the limit of
detection (100 CFU for Figures A and B; 1.7  105 IAV genome copies for Figures C and D). The Mann Whitney U Test was used to compare control (adjuvant alone) and WCV-
treated mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Effect of WCV on pneumococcal OM type in mice following co-infection.
Pneumococcal isolate Group 6 days post-IAV 12 days post-IAV
OM type OM type
No OM Unilateral Bilateral pa No OM Unilateral Bilateral p
EF3030 Adjuvant 0/18 (0)b 5/18 (28) 13/18 (72) 0.167 8/20 (40) 6/20 (30) 6/20 (30) 0.931
WCV 4/21 (19) 6/21 (29) 11/21 (52) 11/25 (44) 6/25 (24) 8/25 (32)
PMP1106 Adjuvant 0/18 (0) 7/18 (39) 11/18 (61) 0.569 8/21 (38) 5/21 (24) 8/21 (38) 0.846
WCV 2/21 (10) 6/21 (29) 13/21 (62) 8/18 (44) 5/18 (28) 5/18 (28)
a Comparison of adjuvant vs WCV, Fisher’s exact test, two-tailed.
b Data are expressed as number of mice/total mice (%).
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small but significant increase in IL-17A responses from mice
administered WCV and co-infected with EF3030, compared to the
adjuvant-control mice (Fig. 4A, p = 0.043).
To investigate the contribution of vaccine-induced antibodies,
we measured WCA-specific IgG in the plasma of vaccinated and
co-infected mice. As expected, IgG responses were significantly
higher in WCV-immunised mice, compared to mice administered
adjuvant (Fig. 4B, p < 0.001).
We sought to further investigate the role of antibodies and IL-
17A in the WCV-mediated reduction of EF3030 in the ears using
mice deficient in antibodies and CD4+ T cells. To determine the role
of CD4+ T cells in the WCV-induced reduction of EF3030 density in
the middle ears, we used the CD4+ T cell-deficient GK1.5 transgenic
mouse strain [24]. To investigate the effect of CD4+ T cells only at
the time of OM development (i.e. following IAV infection), we
depleted WT mice of CD4+ T cells via i.p. administration of the
Fig. 3. Effect of WCV on pneumococcal OM 12 days post-IAV. Mice were administered one dose of either adjuvant (open squares) or WCV (closed squares) subcutaneously
and then co-infected with pneumococci (EF3030, left panel or PMP1106, right panel) and IAV as depicted in Fig. 1A. Pneumococcal and IAV levels in the nasopharynx and
middle ears were determined 12 days post-IAV infection for mice co-infected with EF3030 (A, C) or PMP1106 (B, D). For the nasopharynx, each data point represents an
individual mouse. Counts from each middle ear are represented as individual data points. All graphs show data pooled from three independent experiments. Red lines show
the median; the dotted line represents the limit of detection (100 CFU for Figures A and B; 1.7  105 IAV genome copies for Figures C and D). The Mann Whitney U Test was
used to compare control (adjuvant alone) and WCV-treated mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
Fig. 4. IL-17A and IgG responses in vaccinated co-infected mice. Mice were administered one dose of adjuvant (open squares) or WCV (closed squares) subcutaneously and
then co-infected (with EF3030 and IAV) as depicted in Fig. 1A. Blood and spleens were harvested 6 days post-IAV infection. WCA-specific IL-17A was measured by ELISA from
the supernatants of splenocyte suspensions that had been stimulated with WCA or PBS for 72 h (A). Anti-WCA IgG responses were measured in plasma (B). Each data point
represents an individual mouse. All graphs show data pooled from three independent experiments; red lines show the median; the dotted line represents the limit of
detection: 10.9 pg/ml of IL-17A, 15.625 AU of IgG, 100 CFU. The Mann Whitney U Test was used to compare immune responses in control (adjuvant alone) and WCV-treated
mice. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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GK1.5 mAb before (at 17 days old) and after (at 23 days old) IAV
infection. Preliminary experiments confirmed that the dosing
schedules chosen effectively depleted CD4+ T cells at the time of
IAV infection, and during the development of IAV-mediated pneu-
mococcal OM, in WT mice (Fig S1). To investigate the role of anti-
bodies in the WCV-mediated reduction of EF3030 in the middle
ears, we used antibody-deficient B6.lMT/ mice. Pneumococcal
and IAV co-infection of B6.lMT/ mice resulted in reduced dis-
semination of pneumococci to the middle ears compared to co-
infection of WT C57BL/6 mice, but dissemination could be
increased by providing B6.lMT/ mice with a source of non-
specific antibodies via administration (passive transfer) of naïve
C57BL/6 mouse serum [25]. We confirmed that passive transfer
of naïve mouse serum to co-infected B6.lMT/ mice enhanced
pneumococcal density in the middle ears of co-infected B6.lMT/
mice (Fig S2, p = 0.003) using the infection timeline described in
Fig. 1A.
To determine if a single dose of WCV administered at 6 days of
age could reduce EF3030 density in the middle ears of co-infected
mice in the absence of CD4+ T cells and antibody responses, we
compared pneumococcal density in the middle ears of vaccinated
and co-infected GK1.5 mice, WT mice depleted of CD4+ T cells,
and B6.lMT/mice. WCV immunisation (compared with adjuvant
alone) no longer reduced EF3030 density in the middle ears follow-
ing co-infection in any of these immune-depleted models (Fig. 5B).
No significant differences were observed between adjuvant and
WCV-immunised immune-deficient mice that developed OM or
the proportion of mice exhibiting bilateral OM (Table 2). In addi-
Fig. 5. Effect of CD4+ T cell and antibody-depletion on the WCV-mediated impact on pneumococcal density following co-infection with EF3030. C57BL/6 (WT), GK1.5 or B6.
lMT/ mice were administered one dose of adjuvant (open squares) or WCV (closed squares) subcutaneously and then co-infected (with EF3030 and IAV) as depicted in
Fig. 1A. CD4+ T cells were depleted in WT mice before and after IAV infection (WT + GK1.5 mAb) as described in the methods. B6.lMT/ mice (lMT/) were administered
naïve serum as described in the methods. Pneumococcal density was measured in the nasopharynx (A) and middle ears (B) at 6 days post-IAV infection. Each nasopharyngeal
data point represents an individual mouse. Counts from each middle ear are represented as individual data points. Red lines show the median; the dotted line represents the
limit of detection (100 CFU). All graphs show data pooled from at least two independent experiments. The Mann Whitney U Test was used to compare adjuvant and WCV-
treated mice in each experimental condition. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 2
Effect of WCV on EF3030 OM six days post-IAV in immune-deficient mice.
Mouse strain Group Number of mice/total mice (%)
No OM Unilateral Bilateral pa
WT Adjuvant 0/18 (0) 5/18 (28) 13/18 (72) 0.167
WCV 4/21 (19) 6/21 (29) 11/21 (52)
GK1.5 Adjuvant 7/20 (35) 5/20 (25) 8/20 (40) 0.386
WCV 3/18 (17) 7/18 (39) 8/18 (44)
WT + GK1.5 mAb Adjuvant 2/16 (13) 2/16 (13) 12/16 (75) 0.613
WCV 1/12 (8) 0/12 (0) 11/12 (92)
lMT/ Adjuvant 4/14 (29) 4/14 (29) 6/14 (43) 0.904
WCV 4/16 (19) 6/16 (38) 6/16 (38)
a Comparison of adjuvant vs WCV, Fisher’s Exact test.
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tion, no significant differences in pneumococcal density in the
nasopharynx were observed between adjuvant and WCV-treated
mice in each model (Fig. 5A, p > 0.05 for all). Taken together, these
results suggest that both CD4+ T cells and antibodies are involved
in the WCV-mediated reduction in EF3030 density observed in
WT co-infected mice.
4. Discussion
Our results demonstrate that although WCV significantly
reduced pneumococcal nasopharyngeal density following IAV
infection, it did not prevent the spread of pneumococci from the
nasopharynx to the middle ear, nor did it enhance clearance of
OM in our model. WCV significantly reduced pneumococcal den-
sity in the middle ears of co-infected mice at the peak of OM in
one of two strains tested. Experiments in immune-deficient/
depleted mice indicate that both CD4+ T cells and antibodies were
involved in the WCV-mediated reduction of pneumococcal isolate
EF3030 density in the middle ears.
There are multiple factors that may explain why WCV was
unable to prevent the development of OM in this model. These
include deficiencies in the immune response of infants to vaccina-
tion [29] and pneumococcal infection [30], the inability to provide
more than one immunisation prior to infection, the limited time
available for mice to mount protective immunity before the induc-
tion of OM, and the magnitude of pneumococcal disease induced
following co-infection, evidenced by almost 100% of co-infected
mice developing pneumococcal OM (Fig. 1). Mechanistically, i.n.
IAV infection induces inflammation in the nasopharynx which
leads to a significant increase in pneumococcal colonisation den-
sity and duration at this site [17,31]. In addition, IAV can disperse
pneumococcal nasopharyngeal biofilms to release virulent bacteria
with a greater propensity to infect the middle ear [32]. To prevent
the development of OM in this model, WCV-induced immunity
would need to control pneumococcal colonisation density and pre-
vent the bacteria from reaching the middle ear, or to mount a rapid
immune response in the middle ear to clear disseminating pneu-
mococci. The former scenario was observed in 4 of 21 and 2 of
21 mice administered WCV and infected with EF3030 and
PMP1106, respectively, compared to none of 18 mice administered
adjuvant alone (Table 1). The observed reduction of EF3030 density
at 6 days post-IAV suggests that WCV temporarily achieved the lat-
ter scenario, but this was not observed for PMP1106. However,
given that there was no reduction in EF3030 density in the middle
ear at a later time point (Fig. 2A), our data demonstrate that WCV
did not enhance the overall clearance of this isolate from the mid-
dle ears. The clinical relevance of the reduced density of EF3030
observed during peak OM is unknown, and histology did not
demonstrate a reduction in inflammation in WCV-immunised
mice. Hearing tests were not conducted as part of this study, but
given that levels of EF3030 in the middle ears of WCV-
immunised mice were comparable to those that have previously
been associated with hearing impairment following co-infection
in this model [16], we do not expect that the WCV-mediated
reduction in density to translate to improved hearing in vaccinated
mice.
Studies of pneumococcal OM in mice have demonstrated that
inflammatory mediators including neutrophil-recruiting IL-17A
[33] and myeloperoxidase [34], as well as TLR2 signalling and neu-
trophil and macrophage recruitment [35], are important in clearing
pneumococci from the middle ear, while T and B cells migrate to
and proliferate at this site several days after infection [36,37].
The role of antibodies in clearing pneumococcal OM remains
uncertain. Clinical evidence from small cohorts suggest that poor
local and systemic antibody responses to pneumococcal antigens
are associated with recurrent OM and upper respiratory tract infec-
tions in children [38,39], but larger studies in high-risk populations
have not confirmed this association [40]. In an experimental co-
infection setting, antibodies, along with neutrophil extracellular
traps, can facilitate pneumococcal multiplication in the middle
ear [25]. WCV-mediated protection against pneumococcal coloni-
sation requires IL-17A but not antibodies, whereas protection
against invasive disease is antibody-mediated [9,41]. As expected,
we observed significantly enhanced systemic IL-17A and antibody
responses in WCV-immunised mice co-infected with EF3030 com-
pared to mice administered adjuvant alone (Fig. 4A, D). It is possi-
ble that theWCV-mediated reduction in EF3030middle ear density
was dependent on immune responses that took place earlier than
6 days post-IAV. Alternatively, higher levels of WCV-induced anti-
bodies and CD4+ T cells (the major subset responsible for IL-17A
production in splenocytes following in vitro stimulation by WCA
[13]) may have migrated to the site of infection. Although we did
not measure IL-17A or antibodies in the middle ear, other studies
have demonstrated successful extravasation of vaccine-specific
antibodies to the middle ear following parenteral immunisation
[42]. It is possible that increased IL-17A and antibody responses
in the middle ear may have initially reduced EF3030 density in
WCV-immunised mice. Our data demonstrating that WCV could
no longer reduce EF3030 density in mice deficient of CD4+ T cells
and antibody responses (Fig. 5B) support this hypothesis. This is
also consistent with data from preclinical evaluation of other
investigational pneumococcal vaccines. For example, Rosch et al.
[43] demonstrated that CD4+ T cells at the time of vaccination were
required to prevent OM following pneumococcal challenge (with
or without IAV co-infection) for both a live attenuated pneumococ-
cal vaccine (BHN97DftsY) delivered i.n., and for i.p. vaccination
with PCV13. These authors also found that protection was associ-
ated with CD4+ T cell-dependent immunoglobulin isotype switch-
ing (mouse IgG2a and 2c for BHN97DftsY, and IgG1 for PCV13) [43].
Additionally, co-infected mice deficient in IL-17A receptor sig-
nalling had higher pneumococcal loads in the middle ears com-
pared to co-infected WT mice following i.n. immunisation with
recombinant PspA and cholera toxin [44]. A role for TH17 responses
in preventing OM is also supported by findings in a cohort of otitis-
prone children in New York. The definition of stringently otitis-
prone (sOP) was assigned to children experiencing three or more
OM episodes within a 6- to 12-month period by Pichichero and col-
leagues [45], who examined OM episodes using tympanocentesis
in 840 children over 10 years. Investigations of immune responses
in this population demonstrated that sOP children showed reduced
production of IL-17A by peripheral blood memory T cells after
stimulation with heat-killed pneumococci or pneumococcal pro-
tein antigens compared to non-sOP children [46,47], suggesting
that reduced CD4+ T cell-mediated IL-17A responses were associ-
ated with an increased risk of recurrent OM.
Antigenic differences between the pneumococcal challenge
strains tested here and the WCV strain, RM200, may have
accounted for the lack of protection observed in our model, and
explain why WCV reduced EF3030 but not PMP1106 density in
the middle ears of co-infected mice. Previous studies have investi-
gated the ability of WCV-induced immune responses to bind to and
kill different strains and serotypes of pneumococci in vitro. Using
ELISA and flow cytometry, Moffitt et al. [21] demonstrated that
WCV-specific antisera bound to a range of pneumococci (repre-
senting 12 serotypes and at least 10 MLST types, and including
both invasive and carriage isolates), and 20 isogenic mutants of
TIGR4 expressing different capsule polysaccharides, at significantly
higher levels compared to adjuvant-specific antisera. However, the
fold-increase in binding was variable between strains. Less strain
variation was observed when IL-17A responses were detected fol-
lowing stimulation of WCV-immunised splenocytes with different
pneumococcal strains (26–43-fold difference in expression [21]),
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and when WCV-specific antibodies were tested for their ability to
induce phagocytosis of pneumococcal strains by mouse peritoneal
cells in vitro (12 to 39% killing [48]).
Pneumococcal strains can vary greatly at the genetic level in a
way that gives rise to considerable variation in pneumococcal sur-
face proteins, which are the targets of the WCV-response. For
example, of 616 pneumococcal carriage isolates, Croucher et al.
[49] identified 39 and 59 variants of pneumococcal surface pro-
teins A (PspA) and C (PspC), respectively. Genetic comparison of
RM200, EF3030 and PMP1106 could show if this is due to differ-
ences in the structure of antigens in all three strains. For example,
differences in PspA may prevent or reduce WCV-induced anti-PspA
from binding to PMP1106 and reducing IAV-induced OM [50].
Differences between the two pneumococcal strains may have
also affected the host response to IAV in our model: mice co-
infected with EF3030 had higher levels of IAV in the nasopharynx
compared with mice co-infected with PMP1106. Diavatopoulos
et al. observed that mice had reduced IAV loads in the presence
of pneumococci [51]. More recently, Ortigoza et al. demonstrated
that pneumococcal neuraminidases (NanA and NanB) reduce IAV
acquisition and shedding [52]. It is possible that differences in sial-
idase expression by pneumococcal strain may have influenced IAV
levels in our model.
Although WCV did not affect the density of nasopharyngeal
colonisation 6 days post-IAV (Fig. 2A and B), it significantly
reduced colonisation density at 12 days post-IAV for both pneumo-
coccal strains tested (Fig. 3A and B). This is consistent with the
broad efficacy of WCV in adult and infant mice [9,10,13,29]. The
enhanced nasopharyngeal clearance observed in WCV-
immunised mice may translate to protection against future epi-
sodes of pneumococcal OM following additional IAV infections. A
second IAV challenge in vaccinated and co-infected mice that
remain colonised with pneumococci would evaluate whether
WCV protection against IAV-induced OM increased with time. High
pneumococcal carriage density is associated with the development
of pneumococcal disease [53–55] and transmission [56,57]. There-
fore, WCV-mediated reductions in carriage may protect against
pneumococcal disease and transmission.
In conclusion, this study was the first to test the effect of WCV
on IAV-induced pneumococcal disease. WCV administration did
not prevent the development of pneumococcal OM, nor speed up
the resolution of infection. However, a strain-dependent reduction
in density of pneumococci in the middle ears was observed. In
addition, WCV reduced the nasopharyngeal density of both isolates
tested. Overall, our data suggest that WCV may not directly impact
on IAV-induced OM within an individual, but may have a
population-level effect due to enhanced clearance of pneumococ-
cal colonisation.
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